Future treatment strategies for neuropathic pain
- PMID: 19655119
- DOI: 10.1007/978-3-540-79090-7_17
Future treatment strategies for neuropathic pain
Abstract
The prevalence of people suffering from chronic pain is extremely high and pain affects millions of people worldwide. As such, persistent pain represents a major health problem and an unmet clinical need. The reason for the high incidence of chronic pain patients is in a large part due to a paucity of effective pain control. An important reason for poor pain control is undoubtedly a deficit in our understanding of the underlying causes of chronic pain and as a consequence our arsenal of analgesic therapies is limited. However, there is considerable hope for the development of new classes of analgesic drugs by targeting novel processes contributing to clinically relevant pain. In this chapter we highlight a number of molecular species which are potential therapeutic targets for future neuropathic pain treatments. In particular, the roles of voltage-gated ion channels, neuroinflammation, protein kinases and neurotrophins are discussed in relation to the generation of neuropathic pain and how by targeting these molecules it may be possible to provide better pain control than is currently available.
Similar articles
-
Ion channel blockers for the treatment of neuropathic pain.Future Med Chem. 2010 May;2(5):803-42. doi: 10.4155/fmc.10.19. Future Med Chem. 2010. PMID: 21426204 Review.
-
Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain.Pharmacol Ther. 2009 Jul;123(1):54-79. doi: 10.1016/j.pharmthera.2009.03.018. Epub 2009 Apr 23. Pharmacol Ther. 2009. PMID: 19393690
-
Current challenges and future prospects in management of neuropathic pain.Expert Rev Neurother. 2008 Nov;8(11):1743-56. doi: 10.1586/14737175.8.11.1743. Expert Rev Neurother. 2008. PMID: 18986244 Review.
-
The role of tetrodotoxin-resistant sodium channels in pain states: are they the next target for analgesic drugs?Curr Opin Investig Drugs. 2008 Jan;9(1):83-9. Curr Opin Investig Drugs. 2008. PMID: 18183535 Review.
-
Future directions in neuropathic pain therapy: closing the translational loop.Oncologist. 2010;15 Suppl 2:24-9. doi: 10.1634/theoncologist.2009-S502. Oncologist. 2010. PMID: 20489194 Review.
Cited by
-
Overcoming obstacles to developing new analgesics.Nat Med. 2010 Nov;16(11):1241-7. doi: 10.1038/nm.2230. Epub 2010 Oct 14. Nat Med. 2010. PMID: 20948534
-
Foamy virus: an available vector for gene transfer in neural cells and other nondividing cells.J Neurovirol. 2010 Nov;16(6):419-26. doi: 10.1007/BF03210847. Epub 2010 Oct 25. J Neurovirol. 2010. PMID: 20969536 Review.
-
Downregulation of microRNA‑29c reduces pain after child delivery by activating the oxytocin‑GABA pathway.Mol Med Rep. 2020 Sep;22(3):1921-1931. doi: 10.3892/mmr.2020.11287. Epub 2020 Jun 26. Mol Med Rep. 2020. PMID: 32705167 Free PMC article.
-
Criticality and degeneracy in injury-induced changes in primary afferent excitability and the implications for neuropathic pain.Elife. 2014 Apr 1;3:e02370. doi: 10.7554/eLife.02370. Elife. 2014. PMID: 24692450 Free PMC article.
-
Therapeutic Strategies for Neuropathic Pain: Potential Application of Pharmacosynthetics and Optogenetics.Mediators Inflamm. 2016;2016:5808215. doi: 10.1155/2016/5808215. Epub 2016 Jan 13. Mediators Inflamm. 2016. PMID: 26884648 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials